Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Japan’s 1st Humira Biosimilar Hits Market
Japan’s first biosimilar for AbbVie’s anti-TNF-α monoclonal antibody Humira (adalimumab) was launched on February 15 by Fujifilm Kyowa Kirin Biologics and its sales partner Mylan EPD. Fujifilm Kyowa Kirin earned approval for its Adalimumab BS Subcutaneous Injection “FKB” in June…
To read the full story
Related Article
- Sandoz Now Distributor of FKB’s Humira Biosimilar in Japan
September 18, 2024
- Sandoz Launches Promotion for Humira Biosimilar in Japan
February 19, 2024
- Sandoz to Take Over Distribution Rights to Japan’s 1st Humira Biosimilar
December 26, 2023
BUSINESS
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Towa Pins NO2 as Key Driver of Nitrosation, Eyes Lower Filter Costs
July 22, 2026
- FRONTEO Taps Bayer Ex-Chair Eiki as Advisor
July 22, 2026
- JCR Grabs 1st Overseas Nod for Izcargo in UAE
July 22, 2026
- Carna Bio’s AML Drug Candidate Earns US Orphan Tag
July 22, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…